Cuorips Inc. (JP:4894)

:4894

4894

Cuorips Inc.

RESEARCH TOOLSreports

Cuorips Inc. (4894) Price & Analysis

1 Followers

4894 Stock Chart & Stats

¥6230.00

¥25.00(0.51%)

At close: Jan 08 4:00 PM EST

¥6230.00

¥25.00(0.51%)

Day’s Range― - ―

52-Week Range¥5,580.00 - ¥12,400.00

Previous CloseN/A

Volume173.60K

Average Volume (3M)107.56K

Market Cap

¥57.23B

Enterprise Value¥53.34B

Total Cash (Recent Filing)¥4.85B

Total Debt (Recent Filing)¥0.00

Price to Earnings (P/E)―

Beta1.15

Next Earnings

May 20, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-30.15

Shares Outstanding8,273,376

10 Day Avg. Volume98,200

30 Day Avg. Volume107,556

Financial Highlights & Ratios

PEG Ratio16.56

Price to Book (P/B)12.03

Price to Sales (P/S)379.55

P/FCF Ratio-74.48

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Balance Sheet StrengthA debt-free balance sheet with FY2025 equity (~¥5.53B) close to total assets (~¥5.74B) provides a durable financial cushion. This reduces insolvency risk, preserves strategic optionality for long development cycles, and supports continued R&D and commercialization without immediate leverage-related pressure.

Revenue AccelerationA ~404% YoY revenue increase in FY2025 signals meaningful commercial traction off a small base, indicating product adoption or successful partnerships. Sustained top-line growth improves prospects for scaling fixed-cost absorption and converting R&D investments into recurring commercialization over the medium term.

Positive Gross ProfitAchieving positive gross profit demonstrates viable unit economics for core therapies and validates pricing/production approaches. As revenues scale, positive gross margins create a pathway to operating leverage, making long-term profitability achievable if SG&A and R&D growth are managed.

Bears Say

Sustained Cash BurnConsistently negative operating and free cash flow (FY2025) create a persistent funding gap. Over the medium term this necessitates external financing or strategic alliances, constrains reinvestment flexibility, and increases operational risk if commercial growth slows or development timelines extend.

Persistent Operating LossesMaterial and recurring operating losses indicate the company has not yet converted revenue growth into sustainable profitability. Continued negative EBIT will erode shareholder equity over time and requires either margin improvement, substantial top-line scaling, or external funding to avoid long-term value dilution.

Financing / Dilution RiskOngoing cash burn and weak cash generation raise the likelihood of equity raises, licensing trade-offs, or debt-like arrangements. Such financing actions can dilute existing shareholders, alter strategic priorities, and impose covenant or partner-driven constraints on long-term R&D and commercialization plans.

4894 FAQ

What was Cuorips Inc.’s price range in the past 12 months?

Cuorips Inc. lowest stock price was ¥5580.00 and its highest was ¥12400.00 in the past 12 months.

What is Cuorips Inc.’s market cap?

Cuorips Inc.’s market cap is ¥57.23B.

When is Cuorips Inc.’s upcoming earnings report date?

Cuorips Inc.’s upcoming earnings report date is May 20, 2026 which is in 44 days.

How were Cuorips Inc.’s earnings last quarter?

Cuorips Inc. released its earnings results on Feb 18, 2026. The company reported -¥30.15 earnings per share for the quarter, missing the consensus estimate of N/A by -¥30.15.

Is Cuorips Inc. overvalued?

According to Wall Street analysts Cuorips Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Cuorips Inc. pay dividends?

Cuorips Inc. does not currently pay dividends.

What is Cuorips Inc.’s EPS estimate?

Cuorips Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cuorips Inc. have?

Cuorips Inc. has 8,273,376 shares outstanding.

What happened to Cuorips Inc.’s price movement after its last earnings report?

Cuorips Inc. reported an EPS of -¥30.15 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.324%.

Which hedge fund is a major shareholder of Cuorips Inc.?

Currently, no hedge funds are holding shares in JP:4894

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Cuorips Inc.

Cuorips Inc. engages in the research, development, manufacture, commercialization, and sale of iPS cell-derived cardiomyocyte sheets. The company offers cellular and tissue-based, and cell processing products. It also provides contract development and manufacturing, and consulting services. The company was formerly known as Cuore Inc. and changed its name to Cuorips Inc. in June 2017. Cuorips Inc. was incorporated in 2017 and is headquartered in Tokyo, Japan.